Docetaxel (Taxotere®) for locally advanced squamous cell carcinoma of the head and neck
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000444
English
Authors' recommendations:
Docetaxel (Taxotere®) is recommended for restricted use within NHS Wales in combination with cisplatin and 5-fluorouracil (5-FU) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Docetaxel (Taxotere®) should be restricted for use as an induction treatment for patients of good performance status (0 or 1) anticipated to be receiving chemo-radiotherapy.
Docetaxel (Taxotere®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=100592&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Taxoids
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.